Fig. 4.
Fig. 4. PLC-β2, GPIIb, and Gαq mRNA levels in the patient and healthy subjects. / cDNA from the patient (P) and healthy subjects (H) was amplified under conditions of linearity of amplification by PCR using specific primers for PLC-β2 corresponding to 3188 nt to 3212 nt (forward) and 4492 nt to 4516 nt (reverse), Gαq (full coding sequence, 1080 nt), and a 1230-bp fragment of GPIIb. The products were transferred to membrane and analyzed by phosphorimaging. The ratios of the PCR products in PLC-β2 to those in Gαq and GPIIb are shown. The findings indicate a decrease in PLC-β2 mRNA in the patient relative to Gαq and GPIIb mRNA.

PLC-β2, GPIIb, and Gαq mRNA levels in the patient and healthy subjects.

cDNA from the patient (P) and healthy subjects (H) was amplified under conditions of linearity of amplification by PCR using specific primers for PLC-β2 corresponding to 3188 nt to 3212 nt (forward) and 4492 nt to 4516 nt (reverse), Gαq (full coding sequence, 1080 nt), and a 1230-bp fragment of GPIIb. The products were transferred to membrane and analyzed by phosphorimaging. The ratios of the PCR products in PLC-β2 to those in Gαq and GPIIb are shown. The findings indicate a decrease in PLC-β2 mRNA in the patient relative to Gαq and GPIIb mRNA.

Close Modal

or Create an Account

Close Modal
Close Modal